BCL2L14

Across TCGA pan-cancer cohorts, BCL2L14 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of BCL2L14’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where BCL2L14 RNA is repressed in tumor relative to normal tissue. In most cancer types BCL2L14 is over-expressed in tumor, although a few such as KIRP and KICH show the opposite, repressed pattern.

KIRP, LUAD, and KICH are the cancer types where BCL2L14 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BCL2L14 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRP	All	All	−0.123	.011	6	view →
LUAD	Female	All	+0.545	<.001	5	view →
KICH	All	All	−0.195	.011	3	view →
PAAD	All	All	+1.462	.015	2	view →
STAD	All	All	+0.865	.037	2	view →
UCEC	All	All	+0.479	.002	2	view →
PRAD	All	All	+0.347	.010	2	view →
BRCA	All	III,IV	−0.315	.029	2	view →
READ	Female	All	+0.714	.010	1	view →
LUSC	Male	III,IV	−0.582	.026	1	view →
KIRC	Female	All	−0.214	.047	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

BCL2L14–KIRP

Open the KIRP breakdown →